186 related articles for article (PubMed ID: 27793003)
1. Evaluation of quantitative assays for the identification of direct signal transducer and activator of transcription 3 (STAT3) inhibitors.
Furtek SL; Matheson CJ; Backos DS; Reigan P
Oncotarget; 2016 Nov; 7(47):77998-78008. PubMed ID: 27793003
[TBL] [Abstract][Full Text] [Related]
2. Changes in signal transducer and activator of transcription 3 (STAT3) dynamics induced by complexation with pharmacological inhibitors of Src homology 2 (SH2) domain dimerization.
Resetca D; Haftchenary S; Gunning PT; Wilson DJ
J Biol Chem; 2014 Nov; 289(47):32538-47. PubMed ID: 25288792
[TBL] [Abstract][Full Text] [Related]
3. Strategies and Approaches of Targeting STAT3 for Cancer Treatment.
Furtek SL; Backos DS; Matheson CJ; Reigan P
ACS Chem Biol; 2016 Feb; 11(2):308-18. PubMed ID: 26730496
[TBL] [Abstract][Full Text] [Related]
4. Novel multiplexed assay for identifying SH2 domain antagonists of STAT family proteins.
Takakuma K; Ogo N; Uehara Y; Takahashi S; Miyoshi N; Asai A
PLoS One; 2013; 8(8):e71646. PubMed ID: 23977103
[TBL] [Abstract][Full Text] [Related]
5. Signal Transducer and Activator of Transcription Protein 3 (STAT3): An Update on its Direct Inhibitors as Promising Anticancer Agents.
Gelain A; Mori M; Meneghetti F; Villa S
Curr Med Chem; 2019; 26(27):5165-5206. PubMed ID: 30027840
[TBL] [Abstract][Full Text] [Related]
6. Discovery of novel STAT3 small molecule inhibitors via in silico site-directed fragment-based drug design.
Yu W; Xiao H; Lin J; Li C
J Med Chem; 2013 Jun; 56(11):4402-12. PubMed ID: 23651330
[TBL] [Abstract][Full Text] [Related]
7. Investigation of the binding determinants of phosphopeptides targeted to the SRC homology 2 domain of the signal transducer and activator of transcription 3. Development of a high-affinity peptide inhibitor.
Coleman DR; Ren Z; Mandal PK; Cameron AG; Dyer GA; Muranjan S; Campbell M; Chen X; McMurray JS
J Med Chem; 2005 Oct; 48(21):6661-70. PubMed ID: 16220982
[TBL] [Abstract][Full Text] [Related]
8. Identification of STAT1 and STAT3 specific inhibitors using comparative virtual screening and docking validation.
Szelag M; Czerwoniec A; Wesoly J; Bluyssen HA
PLoS One; 2015; 10(2):e0116688. PubMed ID: 25710482
[TBL] [Abstract][Full Text] [Related]
9. Characterization of molecular recognition of STAT3 SH2 domain inhibitors through molecular simulation.
Park IH; Li C
J Mol Recognit; 2011; 24(2):254-65. PubMed ID: 21360612
[TBL] [Abstract][Full Text] [Related]
10. Cytosolic delivery of peptidic STAT3 SH2 domain inhibitors.
Cerulli RA; Shehaj L; Tosic I; Jiang K; Wang J; Frank DA; Kritzer JA
Bioorg Med Chem; 2020 Jun; 28(12):115542. PubMed ID: 32503696
[TBL] [Abstract][Full Text] [Related]
11. Alpha-Based Multiplexed Assay for Identifying SH2 Domain Antagonists.
Asai A; Takakuma K
Methods Mol Biol; 2017; 1555():351-356. PubMed ID: 28092042
[TBL] [Abstract][Full Text] [Related]
12. Small-molecule compounds targeting the STAT3 DNA-binding domain suppress survival of cisplatin-resistant human ovarian cancer cells by inducing apoptosis.
Huang W; Liu Y; Wang J; Yuan X; Jin HW; Zhang LR; Zhang JT; Liu ZM; Cui JR
Eur J Med Chem; 2018 Sep; 157():887-897. PubMed ID: 30145375
[TBL] [Abstract][Full Text] [Related]
13. Rational drug design of benzothiazole-based derivatives as potent signal transducer and activator of transcription 3 (STAT3) signaling pathway inhibitors.
Gao D; Jin N; Fu Y; Zhu Y; Wang Y; Wang T; Chen Y; Zhang M; Xiao Q; Huang M; Li Y
Eur J Med Chem; 2021 Apr; 216():113333. PubMed ID: 33689932
[TBL] [Abstract][Full Text] [Related]
14. A novel non-phosphorylated potential antitumoral peptide inhibits STAT3 biological activity.
Dourlat J; Liu WQ; Sancier F; Edmonds T; Pamonsinlapatham P; Cruzalegui F; Garbay C
Biochimie; 2009 Aug; 91(8):996-1002. PubMed ID: 19470402
[TBL] [Abstract][Full Text] [Related]
15. A high-throughput fluorescence polarization assay for discovering inhibitors targeting the DNA-binding domain of signal transducer and activator of transcription 3 (STAT3).
Shih PC; Yang Y; Parkinson GN; Wilderspin A; Wells G
Oncotarget; 2018 Aug; 9(66):32690-32701. PubMed ID: 30220975
[TBL] [Abstract][Full Text] [Related]
16. A high-throughput fluorescence polarization assay for signal transducer and activator of transcription 3.
Schust J; Berg T
Anal Biochem; 2004 Jul; 330(1):114-8. PubMed ID: 15183768
[TBL] [Abstract][Full Text] [Related]
17. Stattic: a small-molecule inhibitor of STAT3 activation and dimerization.
Schust J; Sperl B; Hollis A; Mayer TU; Berg T
Chem Biol; 2006 Nov; 13(11):1235-42. PubMed ID: 17114005
[TBL] [Abstract][Full Text] [Related]
18. Discovery of N-substituted sulfamoylbenzamide derivatives as novel inhibitors of STAT3 signaling pathway based on Niclosamide.
Wang X; Wu K; Fang L; Yang X; Zheng N; Du Z; Lu Y; Xie Z; Liu Z; Zuo Z; Ye F
Eur J Med Chem; 2021 Jun; 218():113362. PubMed ID: 33774344
[TBL] [Abstract][Full Text] [Related]
19. Novel STAT3 small-molecule inhibitors identified by structure-based virtual ligand screening incorporating SH2 domain flexibility.
Kong R; Bharadwaj U; Eckols TK; Kolosov M; Wu H; Cruz-Pavlovich FJS; Shaw A; Ifelayo OI; Zhao H; Kasembeli MM; Wong STC; Tweardy DJ
Pharmacol Res; 2021 Jul; 169():105637. PubMed ID: 33932608
[TBL] [Abstract][Full Text] [Related]
20. In silico simulations of STAT1 and STAT3 inhibitors predict SH2 domain cross-binding specificity.
Szelag M; Sikorski K; Czerwoniec A; Szatkowska K; Wesoly J; Bluyssen HA
Eur J Pharmacol; 2013 Nov; 720(1-3):38-48. PubMed ID: 24211327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]